• 1
    Abernethy D.R. Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients. Clin. Geriatr. Med. (1990) 6 285292.
  • 2
    McLean A.J., Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. (2004) 56 163184.
  • 3
    Hochhaus G., Barrett J.S., Derendorf H. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J. Clin. Pharmacol. (2000) 40 908917.
  • 4
    Le Couteur D.G., Naganathan V., Cogger V.C., Cumming R.G., McLean A.J. Pharmacotherapy in the elderly: clinical issues and perspectives. In: KohliK., GuptaM., TejwaniS. (Eds), Contemporary perspectives on clinical therapeutics, Elsevier, Amsterdam, 2006, pp. 709722.
  • 5
    Fried L.P., Tangen C.M., Walston J. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. (2001) 56 M146M156.
  • 6
    Reuben D.B., Borok G.M., Wolde-Tsadik G., Ershoff D.H., Fishman L.K., Ambrosini V.L. et al. A randomized trial of comprehensive geriatric assessment in the care of hospitalized patients. N. Engl. J. Med. (1995) 332 13451350.
  • 7
    Reuben D.B., Frank J.C., Hirsch S.H., McGuigan K.A., Maly R.C. A randomized clinical trial of outpatient comprehensive geriatric assessment coupled with an intervention to increase adherence to recommendations. J. Am. Geriatr. Soc. (1999) 47 269276.
  • 8
    Ferrucci L., Guralnik J.M., Cavazzini C., Bandinelli S., Lauretani F., Bartali B. et al. The frailty syndrome: a critical issue in geriatric oncology. Crit. Rev. Oncol. Hematol. (2003) 46 127137.
  • 9
    Belcher V.N., Fried T.R., Agostini J.V., Tinetti M.E. Views of older adults on patient participation in medication-related decision making. J. Gen. Intern. Med. (2006) 21 298303.
  • 10
    Phelan E.A., Anderson L.A., LaCroix A.Z., Larson E.B. Older adults’ views of ‘‘successful aging’’– how do they compare with researchers’ definitions? J. Am. Geriatr. Soc. (2004) 52 211216.
  • 11
    Guralnik J.M., Simonsick E.M., Ferrucci L., Glynn R.J., Berkman L.F., Blazer D.G. et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J. Gerontol. (1994) 49 M85M94.
  • 12
    Ried L.D., Johnson R.E., Gettman D.A. Benzodiazepine exposure and functional status in older people. J. Am. Geriatr. Soc. (1998) 46 7176.
  • 13
    Gray S.L., Penninx B.W., Blough D.K., Artz M.B., Guralnik J.M., Wallace R.B., et al. Benzodiazepine use and physical performance in community-dwelling older women. J. Am. Geriatr. Soc. (2003) 51 15631570.
  • 14
    Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch. Intern. Med. (1997) 157 15311536.
  • 15
    Hanlon J.T., Fillenbaum G.G., Kuchibhatla M., Artz M.B., Boult C., Gross C.R. et al. Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med. Care (2002) 40 166176.
  • 16
    Onder G., Landi F., Liperoti R., Fialova D., Gambassi G., Bernabei R. Impact of inappropriate drug use among hospitalized older adults. Eur. J. Clin. Pharmacol. (2005) 61 453459.
  • 17
    Savo A., Maiorano P.M., Onder G., Bernabei R. Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function? Expert Opin. Pharmacother. (2004) 5 407413.
  • 18
    Agostini J.V., Han L., Tinetti M.E. The relationship between number of medications and weight loss or impaired balance in older adults. J. Am. Geriatr. Soc. (2004) 52 17191723.
  • 19
    Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA (2003) 289 16811690.
  • 20
    Dobkin B.H. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil. Neural. Repair (2005) 19 259263.
  • 21
    Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., Nicholson G.C. Falls and 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arch. Intern. Med. (2002) 162 2381.
  • 22
    Lunenfeld B. Androgen therapy in the aging male. World J. Urol. (2003) 21 292305.
  • 23
    Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhager W.H., Babarskiene M.R. et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 352 13471351.
  • 24
    Spence J.D. Preventing dementia by treating hypertension and preventing stroke. Hypertension (2004) 44 2021.
  • 25
    Anson O., Paran E. Hypertension and cognitive functioning among the elderly: an overview. Am. J. Ther. (2005) 12 359365.
  • 26
    Le Couteur D.G., Bailey L., Naganathan V. Beta-blockers and heart failure in older people. Eur. Heart J. (2006) 27 887888.
  • 27
    Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 355 15751581.
  • 28
    McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C. et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. (2001) 344 333340.
  • 29
    Nair B.R. Evidence based medicine for older people: available, accessible, acceptable, adaptable? Aust. J. Ageing (2002) 21 5860.
  • 30
    Le Quintrec J.L., Bussy C., Golmard J.L., Herve C., Baulon A., Piette F. Randomized controlled drug trials on very elderly subjects: descriptive and methodological analysis of trials published between 1990 and 2002 and comparison with trials on adults. J. Gerontol. A Biol. Sci. Med. Sci. (2005) 60 340344.
  • 31
    Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. (2006) CD005593.
  • 32
    Loy C., Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. (2006) CD001747.
  • 33
    Walker J., Wynne H. Review: the frequency and severity of adverse drug reactions in elderly people. Age Ageing (1994) 23 255259.
  • 34
    Beyth R.J., Shorr R.I. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging (1999) 14 231239.
  • 35
    Bordet R., Gautier S., Le Louet H., Dupuis B., Caron J. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur. J. Clin. Pharmacol. (2001) 56 935941.
  • 36
    Carbonin P., Pahor M., Bernabei R., Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J. Am. Geriatr. Soc. (1991) 39 10931099.
  • 37
    Hurwitz N. Predisposing factors in adverse reactions to drugs. Br. Med. J. (1969) 1 536539.
  • 38
    Kellaway G.S., McCrae E. Intensive monitoring for adverse drug effects in patients discharged from acute medical wards. N. Z. Med. J. (1973) 78 525528.
  • 39
    Pouyanne P., Haramburu F., Imbs J.L., Begaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ (2000) 320 1036.
  • 40
    Routledge P.A., O'Mahony M.S., Woodhouse K.W. Adverse drug reactions in elderly patients. Br. J. Clin. Pharmacol. (2004) 57 121126.
  • 41
    Atkin P.A., Veitch P.C., Veitch E.M., Ogle S.J. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging (1999) 14 141152.
  • 42
    Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279 12001205.
  • 43
    Mjorndal T., Boman M.D., Hagg S., Backstrom M., Wiholm B.E., Wahlin A. et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol. Drug Saf. (2002) 11 6572.
  • 44
    Mannesse C.K., Derkx F.H., De Ridder M.A., Man in ‘t Veld A.J., Van Der Cammen T.J. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing (2000) 29 3539.
  • 45
    Einarson T.R. Drug-related hospital admissions. Ann. Pharmacother. (1993) 27 832840.
  • 46
    Atkin P.A., Shenfield G.M. Medication-related adverse reactions and the elderly: a literature review. Adverse Drug React. Toxicol. Rev. (1995) 14 175191.
  • 47
    Bootman J.L., Harrison D.L., Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch. Intern. Med. (1997) 157 20892096.
  • 48
    Burgess C.L., Holman C.D., Satti A.G. Adverse drug reactions in older Australians, 1981–2002. Med. J. Aust. (2005) 182 267270.
  • 49
    Gurwitz J.H., Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann. Intern. Med. (1991) 114 956966.
  • 50
    Chan M., Nicklason F., Vial J.H. Adverse drug events as a cause of hospital admission in the elderly. Intern. Med. J. (2001) 31 199205.
  • 51
    Hernandez-Diaz S., Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch. Intern. Med. (2000) 160 20932099.
  • 52
    Gurwitz J.H., Avorn J., Bohn R.L., Glynn R.J., Monane M., Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA (1994) 272 781786.
  • 53
    Johnson A.G. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging (1998) 12 1727.
  • 54
    Henry D., Page J., Whyte I., Nanra R., Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br. J. Clin. Pharmacol. (1997) 44 8590.
  • 55
    Fisher A.A., Le Couteur D.G. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf. (2001) 24 3957.
  • 56
    Cumming R.G., Nevitt M.C., Cummings S.R. Epidemiology of hip fractures. Epidemiol. Rev. (1997) 19 244257.
  • 57
    Cumming R.G. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging (1998) 12 4353.
  • 58
    Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J. Am. Geriatr. Soc. (1999) 47 4050.
  • 59
    Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J. Am. Geriatr. Soc. (1999) 47 3039.
  • 60
    Liu B., Anderson G., Mittmann N., To T., Axcell T., Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet (1998) 351 13031307.
  • 61
    Hien le T.T., Cumming R.G., Cameron I.D., Chen J.S., Lord S.R., March L.M. et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J. Am. Geriatr. Soc. (2005) 53 12901295.
  • 62
    Macdonald J.B., Macdonald E.T. Barbiturates and fractures. Br. Med. J. (1977) 2 891.
  • 63
    Ray W.A., Griffin M.R., Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA (1989) 262 33033307.
  • 64
    Ray W.A., Griffin M.R., Schaffner W., Baugh D.K., Melton L.J. III. Psychotropic drug use and the risk of hip fracture. N. Engl. J. Med. (1987) 316 363369.
  • 65
    Cumming R.G., Le Couteur D.G. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs (2003) 17 825837.
  • 66
    Moreland J.D., Richardson J.A., Goldsmith C.H., Clase C.M. Muscle weakness and falls in older adults: a systematic review and meta-analysis. J. Am. Geriatr. Soc. (2004) 52 11211129.
  • 67
    Moore A.R., O'Keeffe S.T. Drug-induced cognitive impairment in the elderly. Drugs Aging (1999) 15 1528.
  • 68
    Hanlon J.T., Horner R.D., Schmader K.E., Fillenbaum G.G., Lewis I.K., Wall W.E. Jr et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin. Pharmacol. Ther. (1998) 64 684692.
  • 69
    Mulsant B.H., Pollock B.G., Kirshner M., Shen C., Dodge H., Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch. Gen. Psychiatry (2003) 60 198203.
  • 70
    Ancelin M.L., Artero S., Portet F., Dupuy A.M., Touchon J., Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ (2006) 332 455459.
  • 71
    Flacker J.M., Cummings V., Mach J.R. Jr, Bettin K., Kiely D.K., Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am. J. Geriatr. Psychiatry (1998) 6 3141.
  • 72
    Anderson G., Kerluke K. Distribution of prescription drug exposures in the elderly: description and implications. J. Clin. Epidemiol. (1996) 49 929935.
  • 73
    Jorgensen T., Johansson S., Kennerfalk A., Wallander M.A., Svardsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann. Pharmacother. (2001) 35 10041009.
  • 74
    Kennerfalk A., Ruigomez A., Wallander M.A., Wilhelmsen L., Johansson S. Geriatric drug therapy and healthcare utilization in the United kingdom. Ann. Pharmacother. (2002) 36 797803.
  • 75
    Sorensen L., Stokes J.A., Purdie D.M., Woodward M., Roberts M.S. Medication management at home: medication-related risk factors associated with poor health outcomes. Age Ageing (2005) 34 626632.
  • 76
    Simons L.A., Tett S., Simons J., Lauchlan R., McCallum J., Friedlander Y. et al. Multiple medication use in the elderly. Use of prescription and non-prescription drugs in an Australian community setting. Med. J. Aust. (1992) 157 242246.
  • 77
    Cohen R.J., Ek K., Pan C.X. Complementary and alternative medicine (CAM) use by older adults: a comparison of self-report and physician chart documentation. J. Gerontol. A Biol. Sci. Med. Sci. (2002) 57 M223M227.
  • 78
    Flaherty J.H., Takahashi R. The use of complementary and alternative medical therapies among older persons around the world. Clin. Geriatr. Med. (2004) 20 179200.
  • 79
    Bressler R. Herb–drug interactions: interactions between Ginkgo biloba and prescription medications. Geriatrics (2005) 60 3033.
  • 80
    MacLennan A.H., Wilson D.H., Taylor A.W. Prevalence and cost of alternative medicine in Australia. Lancet (1996) 347 569573.
  • 81
    Hoblyn J.C., Brooks J.O. III. Herbal supplements in older adults. Consider interactions and adverse events that may result from supplement use. Geriatrics (2005) 60 2223.
  • 82
    Dergal J.M., Gold J.L., Laxer D.A., Lee M.S., Binns M.A., Lanctot K.L. et al. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging (2002) 19 879886.
  • 83
    Jiang X., Williams K.M., Liauw W.S., Ammit A.J., Roufogalis B.D., Duke C.C. et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. (2005) 59 425432.
  • 84
    Rochon P.A., Gurwitz J.H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ (1997) 315 10961099.
  • 85
    Carlson J.E. Perils of polypharmacy: 10 steps to prudent prescribing. Geriatrics (1996) 51 2630, 35.
  • 86
    Avorn J., Bohn R.L., Mogun H., Gurwitz J.H., Monane M., Everitt D. et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am. J. Med. (1995) 99 4854.
  • 87
    Lawlor D.A., Patel R., Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ (2003) 327 712717.
  • 88
    Adler A.I. Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials. Clin. Med. (2001) 1 472477.
  • 89
    Kassab E., McFarlane S.I., Sower J.R. Vascular complications in diabetes and their prevention. Vasc. Med. (2001) 6 249255.
  • 90
    Campbell A.J., Robertson M.C., Gardner M.M., Norton R.N., Buchner D.M. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J. Am. Geriatr. Soc. (1999) 47 850853.
  • 91
    Froom J., Trilling J. Reducing antihypertensive medication use in nursing home patients. Arch. Fam. Med. (2000) 9 378383.
  • 92
    Ekbom T., Lindholm L.H., Oden A., Dahlof B., Hansson L., Wester P.O. et al. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J. Intern. Med. (1994) 235 581588.
  • 93
    Straand J., Sandvik H. Stopping long-term drug therapy in general practice. How well do physicians and patients agree? Fam. Pract. (2001) 18 597601.
  • 94
    Matsuura M. Patient satisfaction with polypharmacy reduction in chronic epileptics. Psychiatry Clin. Neurosci. (2000) 54 249253.
  • 95
    Graves T., Hanlon J.T., Schmader K.E., Landsman P.B., Samsa G.P., Pieper C.F. et al. Adverse events after discontinuing medications in elderly outpatients. Arch. Intern. Med. (1997) 157 22052210.
  • 96
    Kennedy J.M., Van Rij A.M., Spears G.F., Pettigrew R.A., Tucker I.G. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br. J. Clin. Pharmacol. (2000) 49 353362.
  • 97
    Woodward M. Deprescribing: achieving better health outcomes for older people through reducing medications. J. Pharm. Pract. Res. (2003) 33 323328.
  • 98
    Sorensen L., Stokes J.A., Purdie D.M., Woodward M., Elliott R., Roberts M.S. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br. J. Clin. Pharmacol. (2004) 58 648664.
  • 99
    Bogunovic O.J., Greenfield S.F. Practical geriatrics: use of benzodiazepines among elderly patients. Psychiatr. Serv. (2004) 55 233235.
  • 100
    Mottram P., Wilson K., Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst. Rev. (2006), CD003491.
  • 101
    Friedman J.H., Feinberg S.S., Feldman R.G. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA (1985) 254 27922795.
  • 102
    Atkin P.A., Stringer R.S., Duffy J.B., Elion C., Ferraris C.S., Misrachi S.R. et al. The influence of information provided by patients on the accuracy of medication records. Med. J. Aust. (1998) 169 8588.
  • 103
    Atkin P.A., Finnegan T.P., Ogle S.J., Shenfield G.M. Are medication record cards useful? Med. J. Aust. (1995) 162 300301.
  • 104
    Crotty M., Rowett D., Spurling L., Giles L.C., Phillips P.A. Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial. Am. J. Geriatr. Pharmacother. (2004) 2 257264.
  • 105
    Sackett D.L., Snow J.C. Compliance in health care. Johns Hopkins University Press, Baltimore, 1979.
  • 106
    Hughes C.M. Medication non-adherence in the elderly: how big is the problem? Drugs Aging (2004) 21 793811.
  • 107
    Osterberg L., Blaschke T. Adherence to medication. N. Engl. J. Med. (2005) 353 487497.
  • 108
    Atkin P.A., Finnegan T.P., Ogle S.J., Shenfield G.M. Functional ability of patients to manage medication packaging: a survey of geriatric inpatients. Age Ageing (1994) 23 113116.
  • 109
    Fawell N.G., Cookson T.L., Scranton S.S. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance. Am. J. Health Syst. Pharm. (1999) 56 25422545.
  • 110
    Marriott J.L., Nation R.L. Splitting tablets. Aust. Prescr. (2002) 25 133135.
  • 111
    Wright D. Medication administration in nursing homes. Nurs. Stand. (2002) 16 3338.
  • 112
    Carnaby-Mann G., Crary M. Pill swallowing by adults with dysphagia. Arch. Otolaryngol. Head Neck Surg. (2005) 131 970975.
  • 113
    Haynes R., Yao X., Degani A., Kripalani S., Garg A., McDonald H. et al. Interventions to enhance medication adherence. Cochrane Database Syst. Rev. (2005), CD000011.
  • 114
    Schmucker D.L. Age-related changes in liver structure and function: implications for disease? Exp. Gerontol. (2005) 40 650659.
  • 115
    Le Couteur D.G., McLean A.J. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin. Pharmacokinet. (1998) 34 359373.
  • 116
    Schmucker D.L. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging (2001) 18 837851.
  • 117
    Le Couteur D.G., Fraser R., Hilmer S., Rivory L.P., McLean A.J. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin. Pharmacokinet. (2005) 44 187200.
  • 118
    Cotreau M.M., Von Moltke L.L., Greenblatt D.J. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet. (2005) 44 3360.
  • 119
    Wynne H.A., Cope L.H., Herd B., Rawlins M.D., James O.F., Woodhouse K.W. The association of age and frailty with paracetamol conjugation in man. Age Ageing (1990) 19 419424.
  • 120
    Summerbell J., Wynne H., Hankey C.R., Williams F.M. The effect of age and frailty upon blood esterase activities and their response to dietary supplementation. Br. J. Clin. Pharmacol. (1993) 36 399404.
  • 121
    Warrington J.S., Greenblatt D.J., Von Moltke L.L. The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J. Pharmacol. Exp. Ther. (2004) 309 730736.
  • 122
    Warrington J.S., Greenblatt D.J., Von Moltke L.L. Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J. Pharmacol. Exp. Ther. (2004) 309 720729.
  • 123
    Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron (1976) 16 3141.
  • 124
    Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. (1999) 130 461470.
  • 125
    Mathew T.H. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med. J. Aust. (2005) 183 138141.
  • 126
    Morike K., Schwab M., Klotz U. Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging (1997) 10 259277.
  • 127
    Miura T., Kojima R., Sugiura Y., Mizutani M., Takatsu F., Suzuki Y. Effect of aging on the incidence of digoxin toxicity. Ann. Pharmacother. (2000) 34 427432.
  • 128
    Triggs E., Charles B. Pharmacokinetics and therapeutic drug monitoring of gentamicin in the elderly. Clin. Pharmacokinet. (1999) 37 331341.
  • 129
    Abernethy D.R., Schwartz J.B., Plachetka J.R., Todd E.L., Egan J.M. Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. Am. J. Cardiol. (1987) 60 697702.
  • 130
    Schnider T.W., Minto C.F., Shafer S.L., Gambus P.L., Andresen C., Goodale D.B. et al. The influence of age on propofol pharmacodynamics. Anesthesiology (1999) 90 15021516.
  • 131
    Greenblatt D.J., Harmatz J.S., Von Moltke L.L., Wright C.E., Shader R.I. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin. Pharmacol. Ther. (2004) 76 467479.
  • 132
    Shi X., Wray D.W., Formes K.J., Wang H.W., Hayes P.M., AH O.Y. et al. Orthostatic hypotension in aging humans. Am. J. Physiol. Heart Circ. Physiol. (2000) 279 H1548H1554.
  • 133
    Verhaeverbeke I., Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf. (1997) 17 105118.
  • 134
    Deedwania P.C., Gottlieb S., Ghali J.K., Waagstein F., Wikstrand J.C. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur. Heart J. (2004) 25 13001309.
  • 135
    Flather M.D., Shibata M.C., Coats A.J., Van Veldhuisen D.J., Parkhomenko A., Borbola J. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. (2005) 26 215225.
  • 136
    Brodde O.E., Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur. J. Pharmacol. (2004) 500 167176.
  • 137
    Owan T.E., Redfield M.M. Epidemiology of diastolic heart failure. Prog. Cardiovasc. Dis. (2005) 47 320332.
  • 138
    Meyer T.E., Kovacs S.J., Ehsani A.A., Klein S., Holloszy J.O., Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J. Am. Coll. Cardiol. (2006) 47 398402.
  • 139
    Wasil T., Lichtman S.M. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist (2005) 10 602612.
  • 140
    Helme R.D., Gibson S.J. The epidemiology of pain in elderly people. Clin. Geriatr. Med. (2001) 17 417431.
  • 141
    Kemp C.A., Ersek M., Turner J.A. A descriptive study of older adults with persistent pain: use and perceived effectiveness of pain management strategies. BMC Geriatr. (2005) 5 12.
  • 142
    Gibson S.J., Helme R.D. Age-related differences in pain perception and report. Clin. Geriatr. Med. (2001) 17 433456.
  • 143
    Larson A.M., Polson J., Fontana R.J., Davern T.J., Lalani E., Hynan L.S. et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 42 13641372.
  • 144
    Whitcomb D.C., Block G.D. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA (1994) 272 18451850.
  • 145
    Mion L.C., McDowell J.A., Heaney L.K. Nutritional assessment of the elderly in the ambulatory care setting. Nurse Pract. Forum (1994) 5 4651.
  • 146
    Zador D.A., Truswell A.S. Nutritional status on admission to a general surgical ward in a Sydney hospital. Aust. N. Z. J. Med. (1987) 17 234240.
  • 147
    Visvanathan R., Penhall R., Chapman I. Nutritional screening of older people in a sub-acute care facility in Australia and its relation to discharge outcomes. Age Ageing (2004) 33 260265.
  • 148
    Shaver H.J., Loper J.A., Lutes R.A. Nutritional status of nursing home patients. J. Parenter. Enteral. Nutr. (1980) 4 367370.
  • 149
    Rikans L.E., Moore D.R. Acetaminophen hepatotoxicity in aging rats. Drug Chem. Toxicol. (1988) 11 237247.
  • 150
    Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. (1999) 131 492501.
  • 151
    Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch. Intern. Med. (1987) 147 15611564.
  • 152
    Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet (1994) 343 687691.
  • 153
    Man-Son-Hing M., Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch. Intern. Med. (2002) 162 541550.
  • 154
    Desbiens N.A. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. J. Am. Geriatr. Soc. (2002) 50 863869.
  • 155
    Johnson C.E., Lim W.K., Workman B.S. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J. Am. Geriatr. Soc. (2005) 53 655659.
  • 156
    Fihn S.D., Callahan C.M., Martin D.C., McDonell M.B., Henikoff J.G., White R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann. Intern. Med. (1996) 124 970979.
  • 157
    Van Walraven C., Austin P.C., Oake N., Wells P., Mamdani M., Forster A.J. The effect of hospitalization on oral anticoagulation control: a population-based study. Thromb. Res. (2007)119 705714.
  • 158
    Wittkowsky A.K., Whitely K.S., Devine E.B., Nutescu E. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. Pharmacotherapy. (2004) 24 600605.
  • 159
    Franchini M. Hemostasis and aging. Crit. Rev. Oncol. Hematol. (2006)60 144151.
  • 160
    Gage B.F., Birman-Deych E., Kerzner R., Radford M.J., Nilasena D.S., Rich M.W. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am. J. Med. (2005) 118 612617.
  • 161
    Gage B.F., Birman-Deych E., Radford M.J., Nilasena D.S., Binder E.F. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch. Intern. Med. (2006) 166 241246.
  • 162
    Bajorek B.V., Krass I., Ogle S.J., Duguid M.J., Shenfield G.M. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J. Am. Geriatr. Soc. (2005) 53 19121920.
  • 163
    Choudhry N.K., Anderson G.M., Laupacis A., Ross-Degnan D., Normand S.L., Soumerai S.B. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ (2006) 332 141145.
  • 164
    Man-Son-Hing M., Gage B.F., Montgomery A.A., Howitt A., Thomson R., Devereaux P.J., et al. Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med. Decis. Making (2005) 25 548559.